A New CEO And Perhaps A New Era At Shire: An Interview With Flemming Ornskov
This article was originally published in PharmAsia News
Executive Summary
Making his public debut as Shire CEO at the World Orphan Drug Congress, Flemming Ornskov spoke about his four-month transition period as Angus Russell’s designated successor, how his background in pediatrics may guide business development, and whether he plans to revise the specialty pharma’s business model or hew to his predecessor’s course.